The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| OMER | +82.55% | -27.39% | -6.2% | -10% |
| S&P | +14.5% | +93.32% | +14.09% | +529% |
Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
Find out if the deal Omeros announced is enough of a reason to buy this stock.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.20M | 3.8% |
| Market Cap | $175.78M | -25.3% |
| Market Cap / Employee | $0.87M | 0.0% |
| Employees | 202 | 2.0% |
| Net Income | -$25.89M | 60.2% |
| EBITDA | -$32.15M | 45.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.90M | -10.2% |
| Accounts Receivable | $28.22M | -4.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $339.25M | -19.1% |
| Short Term Debt | $42.76M | 71.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -49.24% | -4.0% |
| Return On Invested Capital | -72.22% | 1.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$21.95M | 52.3% |
| Operating Free Cash Flow | -$21.94M | 52.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -1.85 | -3.71 | -2.61 | -0.82 | -75.27% |
| Price to Tangible Book Value | -1.85 | -3.71 | -2.61 | -0.82 | -75.27% |
| Price to Free Cash Flow TTM | 2.75 | - | |||
| Enterprise Value to EBITDA | -15.36 | -25.62 | -24.22 | -16.45 | 86.26% |
| Free Cash Flow Yield | 36.4% | - | |||
| Return on Equity | -576.3% | - | |||
| Total Debt | $433.44M | $423.28M | $415.05M | $382.01M | -14.03% |
OMER earnings call for the period ending March 31, 2020.
OMER earnings call for the period ending December 31, 2019.
OMER earnings call for the period ending September 30, 2019.
OMER earnings call for the period ending June 30, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
